The Food and Drug Administration has rejected a bid to get MDMA approved as a therapy aid for people with post-traumatic stress disorder, a decision that puts off a major milestone for the field of psychedelics. The verdict Friday comes at a pivotal time for this area of research, which has, after decades of dismissal from top drug regulators and companies, recently gained momentum through the work of advocacy groups and powerful organizations like the Department of Veterans Affairs. A bipartisan group of 80 lawmakers this month urged the Biden administration to approve the treatment developed by Lykos Therapeutics, a California-based biotechnology company.
Read the full article: In Tone-Setting Verdict, FDA Rejects MDMA as a Therapy Aid for PTSD //
Source: https://www.healthcaredive.com/news/fda-mdma-therapy-rejection-psychedelics-lykos/723902